阿拉韦罗 (Chinese Wikipedia)
Analysis of information sources in references of the Wikipedia article "阿拉韦罗" in Chinese language version.
refsWebsite
Global rank
Chinese rank
6th place
4th place
1st place
1st place
low place
low place
low place
low place
low place
low place
11th place
332nd place
aidsmeds.com
- Aplaviroc (GSK-873,140). AIDSmeds.com. October 25, 2005 [September 5, 2008]. （原始内容存档于January 13, 2007）.
archive.org
- Borthwick AD. 2,5-Diketopiperazines: synthesis, reactions, medicinal chemistry, and bioactive natural products. Chemical Reviews. July 2012, 112 (7): 3641–3716. PMID 22575049. doi:10.1021/cr200398y.
- Nakata H, Maeda K, Miyakawa T, Shibayama S, Matsuo M, Takaoka Y, et al. Potent anti-R5 human immunodeficiency virus type 1 effects of a CCR5 antagonist, AK602/ONO4128/GW873140, in a novel human peripheral blood mononuclear cell nonobese diabetic-SCID, interleukin-2 receptor gamma-chain-knocked-out AIDS mouse model. Journal of Virology. February 2005, 79 (4): 2087–2096. PMC 546550
. PMID 15681411. doi:10.1128/jvi.79.4.2087-2096.2005. - Nichols WG, Steel HM, Bonny T, Adkison K, Curtis L, Millard J, et al. Hepatotoxicity observed in clinical trials of aplaviroc (GW873140). Antimicrobial Agents and Chemotherapy. March 2008, 52 (3): 858–865. PMC 2258506 . PMID 18070967. doi:10.1128/aac.00821-07.
doi.org
- Borthwick AD. 2,5-Diketopiperazines: synthesis, reactions, medicinal chemistry, and bioactive natural products. Chemical Reviews. July 2012, 112 (7): 3641–3716. PMID 22575049. doi:10.1021/cr200398y.
- Nakata H, Maeda K, Miyakawa T, Shibayama S, Matsuo M, Takaoka Y, et al. Potent anti-R5 human immunodeficiency virus type 1 effects of a CCR5 antagonist, AK602/ONO4128/GW873140, in a novel human peripheral blood mononuclear cell nonobese diabetic-SCID, interleukin-2 receptor gamma-chain-knocked-out AIDS mouse model. Journal of Virology. February 2005, 79 (4): 2087–2096. PMC 546550 . PMID 15681411. doi:10.1128/jvi.79.4.2087-2096.2005.
- Nichols WG, Steel HM, Bonny T, Adkison K, Curtis L, Millard J, et al. Hepatotoxicity observed in clinical trials of aplaviroc (GW873140). Antimicrobial Agents and Chemotherapy. March 2008, 52 (3): 858–865. PMC 2258506 . PMID 18070967. doi:10.1128/aac.00821-07.
- Currier J, Lazzarin A, Sloan L, Clumeck N, Slims J, McCarty D, et al. Antiviral activity and safety of aplaviroc with lamivudine/zidovudine in HIV-infected, therapy-naive patients: the ASCENT (CCR102881) study. Antiviral Therapy. 2008, 13 (2): 297–306. PMID 18505181. S2CID 21839689. doi:10.1177/135965350801300204 .
nih.gov
ncbi.nlm.nih.gov
- Borthwick AD. 2,5-Diketopiperazines: synthesis, reactions, medicinal chemistry, and bioactive natural products. Chemical Reviews. July 2012, 112 (7): 3641–3716. PMID 22575049. doi:10.1021/cr200398y.
- Nakata H, Maeda K, Miyakawa T, Shibayama S, Matsuo M, Takaoka Y, et al. Potent anti-R5 human immunodeficiency virus type 1 effects of a CCR5 antagonist, AK602/ONO4128/GW873140, in a novel human peripheral blood mononuclear cell nonobese diabetic-SCID, interleukin-2 receptor gamma-chain-knocked-out AIDS mouse model. Journal of Virology. February 2005, 79 (4): 2087–2096. PMC 546550 . PMID 15681411. doi:10.1128/jvi.79.4.2087-2096.2005.
- Nichols WG, Steel HM, Bonny T, Adkison K, Curtis L, Millard J, et al. Hepatotoxicity observed in clinical trials of aplaviroc (GW873140). Antimicrobial Agents and Chemotherapy. March 2008, 52 (3): 858–865. PMC 2258506 . PMID 18070967. doi:10.1128/aac.00821-07.
- Currier J, Lazzarin A, Sloan L, Clumeck N, Slims J, McCarty D, et al. Antiviral activity and safety of aplaviroc with lamivudine/zidovudine in HIV-infected, therapy-naive patients: the ASCENT (CCR102881) study. Antiviral Therapy. 2008, 13 (2): 297–306. PMID 18505181. S2CID 21839689. doi:10.1177/135965350801300204 .
retroconference.org
- Maeda K, Ogata H, Harada S, Tojo Y, Miyakawa T, Nakata H, et al. Determination of binding sites of a unique CCR5 inhibitor AK602 on human CCR5 (PDF). 11th conference on retroviruses and opportunistic infections. San Francisco, CA. 2004. （原始内容 (PDF)存档于November 3, 2005）.
semanticscholar.org
api.semanticscholar.org
- Currier J, Lazzarin A, Sloan L, Clumeck N, Slims J, McCarty D, et al. Antiviral activity and safety of aplaviroc with lamivudine/zidovudine in HIV-infected, therapy-naive patients: the ASCENT (CCR102881) study. Antiviral Therapy. 2008, 13 (2): 297–306. PMID 18505181. S2CID 21839689. doi:10.1177/135965350801300204 .
thebody.com
- Moyle G. The Last Word on Aplaviroc: A CCR5 Antagonist With Poor Efficacy. The Body. December 19, 2006 [September 5, 2008]. （原始内容存档于6 October 2008）.
web.archive.org
- Maeda K, Ogata H, Harada S, Tojo Y, Miyakawa T, Nakata H, et al. Determination of binding sites of a unique CCR5 inhibitor AK602 on human CCR5 (PDF). 11th conference on retroviruses and opportunistic infections. San Francisco, CA. 2004. （原始内容 (PDF)存档于November 3, 2005）.
- Aplaviroc (GSK-873,140). AIDSmeds.com. October 25, 2005 [September 5, 2008]. （原始内容存档于January 13, 2007）.
- Moyle G. The Last Word on Aplaviroc: A CCR5 Antagonist With Poor Efficacy. The Body. December 19, 2006 [September 5, 2008]. （原始内容存档于6 October 2008）.